Bendroflumethiazide

This classification denotes a thiazide diuretic with the molecular formula C15H14F3N3O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5Q52X6ICJI, chemically known as 3,4-dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-2h-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide but generally known as bendroflumethiazide, which bears US NIH Compound Identifier 2315. European Medicines Agency schedules Bendroflumethiazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05711MIG. The term BENDROFLUMETHIAZIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules bendroflumethiazide in its Anatomical Therapeutic Chemical (ATC) Classification. BENDROFLUMETHIAZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bendroflumethiazide under HS 29350090 and SITC 51580. As of Q4 2014, BENDROFLUMETHIAZIDE remains the US FDA Preferred Term for this commodity. Bendroflumethiazide bears US NLM identifiers UMLS ID C0701080 and NCI Concept Code C47410. SMILES: S1(=O)(=O)NC(NC2C1CC(S(=O)(=O)N)C(C2)C(F)(F)F)CC1CCCCC1.